ライフサイエンスコーパス: rationale

1 out their recommendations and the underlying rationale.

2 ded there is a strong scientific and ethical rationale.

3 treatment recommendations and the underlying rationale.

4 Rationale: A human model to better understand tuberculos

5 Rationale: A recent randomized controlled trial showed t

6 Rationale: A subpopulation of B cells (age-associated B

7 Rationale: Acute cellular rejection (ACR) is common duri

8 Rationale: Acute kidney injury (AKI), a common complicat

9 Rationale: Acute rejection, manifesting as lymphocytic i

10 Rationale: Acute respiratory distress syndrome (ARDS) la

11 Rationale: Admissions to ICUs are common during terminal

12 Rationale: Advances in neonatal critical care have great

13 Rationale: Adverse events have limited the use of bronch

14 Rationale: Aerosol generation with modes of oxygen thera

15 Our findings provide a rationale against the combination of the nucleoside anal

16 Rationale: Aging is one of the strongest risk factors fo

17 Rationale: Although elevated air pollution exposure impa

18 Rationale: Although proposed as a clinical prompt to sep

19 Rationale: Although relatives of patients with familial

20 Rationale: Although the carcinogenicity of diesel engine

21 Rationale: Alveolar epithelial cell (AEC) injury and dys

22 w, we highlight the emerging pharmacological rationale and clinical development of dual-pathway inhib

23 We also discuss the rationale and clinical outcome of current therapeutic st

24 PfCyRPA and PfRipr, this review explores the rationale and future potential of the RCR complex as a P

25 The goal of this report is to provide a rationale and overview of the FDG PET/CT Profile claims

26 We discuss rationale and practical application of venetoclax in fir

27 potentially in barley plants and establish a rationale and strategy for enhancing FHB resistance in b

28 , it is ever more important to develop sound rationale and strategy for selecting first-line and trea

29 of the 21 items in ARRIVE 2.0, including the rationale and supporting evidence for their inclusion in

30 Here we describe the rationale and ultimate design of a comprehensive biomark

31 Rationale: Antenatal factors, such as chorioamnionitis,

32 Rationale: Antenatal inflammation with placental dysfunc

33 Rationale: Asbestos exposure is associated with a dose-d

34 cepts underlying the biology and therapeutic rationale behind B-cell-directed therapeutics in MS, and

35 point inhibitor anti-PD-1, strengthening the rationale behind combination therapy with oncolytic viru

36 natumomab or CD19CAR T-cell therapy, and the rationale behind each decision.

37 E) document, which serves (1) to explain the rationale behind each item in the guidelines, (2) to cla

38 on document, which serves (1) to explain the rationale behind each item in the guidelines, (2) to cla

39 llowed by a discussion of the motivation and rationale behind semi-artificial photosynthesis.

40 ely contact ion-pairs, which constitutes the rationale behind the "water-in-salt" concept.

41 Here, we discuss the rationale behind the chemical modifications that have be

42 Correspondingly, the rationale behind the recommendations shifted with guidel

43 the years 2015-2020, will first describe the rationale behind these antibody mimics, and the differen

44 The rationale behind these programs is discussed.

45 In this review, we discuss the rationale behind this intervention and the evidence for

46 Emphasis is placed on the rationale behind warhead choice, optimization approach,

47 Rationale: Bronchopulmonary dysplasia is a heterogeneous

48 wever, that authorities might agree with the rationale but not the implementation of such a massive a

49 Rationale: Chronic obstructive pulmonary disease (COPD)

50 Rationale: Chronic obstructive pulmonary disease (COPD)

51 PARPis identified sensitivity biomarkers and rationale combination strategies that can target BRCA wi

52 Rationale: Complement is crucial for host defense but ma

53 combination of scientific and administrative rationale contributed to favorable outcomes after major

54 Rationale: Coronavirus disease (COVID-19) is a global th

55 Rationale: Coronavirus disease (COVID-19) is caused by s

56 We describe the theoretical rationales, current states of the science, field-wide ch

57 Rationale: Cystic fibrosis (CF) is a life-shortening, mu

58 This article summarizes the rationale data reviewed by the CLSI in June 2018.

59 Rationale: Declining lung function in patients with inte

60 Rationale: Deficits in infant lung function-including th

61 ices for periodontal procedures, prescribing rationale, demographic and dental practice information,

62 Rationale: Despite therapeutic progress in treating cyst

63 Rationale: Development of diagnostic tools with improved

64 Rationale: Direct evidence for persistence of Mycobacter

65 Rationale: Emerging evidence supports a crucial role for

66 Rationale: Enhancing non-CFTR (cystic fibrosis transmemb

67 Rationale: Exogenous angiotensin II increases mean arter

68 Rationale: Exposure to air pollution during intrauterine

69 such as sensor/analyte interactions, design rationale, fabrication, characterization, sensitivity, a

70 Rationale: Few data exist to guide early adjunctive ther

71 lved in GEM resistance and provides a strong rationale for a PC therapy addressing the combined treat

72 this work may contribute to the preclinical rationale for a precision medicine trial of the WEE1 inh

73 d adaptive hyperinflammation and support the rationale for an IL-18-driven subclass of hyperinflammat

74 and tables with additional details about the rationale for and implementation of each recommendation,

75 The rationale for and knowledge gaps related to each of thes

76 storical perspective, this review provides a rationale for checking factors that will be key for the

77 : Results from this study provide additional rationale for chronic azithromycin use in PA-positive pa

78 These data support the rationale for clinical development of TTK inhibition as

79 toma and PFA ependymoma, thereby providing a rationale for clinical trials of these approaches in hum

80 We provide strong rationale for clinical use of FFPE-derived RNA based on

81 cancer collective invasion pack and provides rationale for co-targeting PDH and GLUT1 to inhibit coll

82 in vitro model of MEKi resistance provided a rationale for combination therapies.

83 We review the rationale for combination therapy and different strategi

84 tive immunomodulatory properties providing a rationale for combining cabozantinib with immunotherapeu

85 Our findings provide rationale for combining DEX and RUX to enhance the lymph

86 d upregulation of PD-L1 expression provide a rationale for combining MYCi with anti-PD-1/PD-L1 therap

87 ith oncogene targeted therapies, providing a rationale for combining these agents with newly develope

88 We highlight the scientific rationale for comprehensive and longitudinal TCR analyse

89 in this analysis does not find a scientific rationale for concluding that fluoropolymers are of low

90 r endocardium in HLHS etiology and provide a rationale for considering endocardial function in regene

91 n the pathogenesis of AD and propose a novel rationale for correction of metabolic inflammation, incr

92 Our studies thus provide a rationale for developing NK cell-based therapies to effe

93 is primary blood product, providing a strong rationale for developing recombinant alternatives.

94 inflammatory heat hypersensitivity provide a rationale for developing TRPM3 antagonists to treat path

95 eceptor 3-mediated mechanism and support the rationale for development of more-specific receptor modu

96 thereby inducing cmo These results provide a rationale for directly targeting SYK and its downstream

97 Overall, our study provides a rationale for employing coarse Raman mapping to substant

98 These findings give a rationale for epidemiologic studies of air pollution to

99 gs, along with the structural and functional rationale for epitope conservation, provide insights for

100 Because there is increasing rationale for establishing both targeted and universal s

101 KRAS-mediated chemoresistance and provide a rationale for exploiting metabolic reprogramming in panc

102 K signaling in iMCD-TAFRO pathogenesis and a rationale for exploring inhibition of the MAPK pathway a

103 afer anticoagulants are needed, provides the rationale for factor XII and XI as targets for such agen

104 opoietic cell transplantation, providing the rationale for further evaluation of PHIs, in the prevent

105 Our results establish a rationale for further investigation of combined BET and

106 These findings provide the rationale for future interventional studies to explore n

107 ollectively, these data provide a compelling rationale for future investigation of Nutlin-3A as an ap

108 of suboptimal hairpin processing provides a rationale for genomic retention of certain miRNA operons

109 his inhibition, thus providing a mechanistic rationale for heterotrimerization with the KAP subunit f

110 g5-mediated transglycosylation, we provide a rationale for how GPI-CWPs are specifically sorted towar

111 4 different amino acid ligands, providing a rationale for how the LBD binding site evolved to accomm

112 inase complex, but will also provide a novel rationale for inhibitor development in the future.

113 failure in COVID-19 patients and provides a rationale for investigating complement inhibitors in fut

114 ivity to SARS-CoV-2 mutants provide a strong rationale for its evaluation as a COVID-19 therapeutic.

115 t of p53 function that would provide a clear rationale for its frequent inactivation in human cancer.

116 egulator of Wnt receptor turnover provides a rationale for its tumor suppressive function and reveals

117 reduced ejection fraction, with theoretical rationale for its use in HF with preserved ejection frac

118 Herein, we summarize the pathobiological rationale for local cytoreduction and the potentially sy

119 and patients with diabetes mellitus provides rationale for monitoring these asthma subgroups for poor

120 This mechanism provides a rationale for multiple therapeutic approaches.

121 ggressive murine models of SCLC, providing a rationale for new combination regimens consisting of CDK

122 This review details the rationale for NMP protocols considering duration of NMP

123 This work provides a fundamental biochemical rationale for nonredundant roles of these RNA demethylas

124 Our results provide rationale for novel therapeutic approaches targeting HIV

125 stem cell state and function and provides a rationale for Nrf2 as a therapeutic target in stem cell-

126 This provides a sound rationale for optimizing venous return during significan

127 ctures of paralogous complexes, we provide a rationale for our observations.

128 n and BZH in patients with EoE and provide a rationale for pharmacologic intervention of ANO1 functio

129 Together, our findings provide a rationale for pharmacological blockade of the AXL signal

130 The most common rationale for prescribing antibiotics with bone grafting

131 This provides a rationale for prospective studies on standardized survei

132 These studies provide a rationale for pursuing enantiomerically pure RJW100 deri

133 al immunization studies that provide a clear rationale for renewed efforts to develop a CD8(+) T cell

134 ed and future applications, and to provide a rationale for selecting optical technologies for molecul

135 ncanonical binding mode in CLK1, providing a rationale for selectivity over the closely related CLK3

136 mpact CVD risk, and 4) is there a sufficient rationale for setting a target for maximally reducing di

137 The majority of studies failed to provide rationale for single-sex studies or the lack of sex-base

138 ign considerations for industry and provides rationale for some of the recommendations included in th

139 There is a rationale for studying EPCR in hemophilia.

140 ssant response in humans and provide further rationale for studying gamma power changes as potential

141 empirical and the underlying mechanisms and rationale for success are unknown.

142 Despite the existing rationale for targeting activated KRAS and its downstrea

143 vivo, and/or in humans) and provide a strong rationale for targeting BRD2/BRD4 for disease treatment

144 in lung carcinogenesis that will inform the rationale for targeting its related regulatory signaling

145 ncreasing proteasome capacity, and provide a rationale for targeting such patients with PI/RAF or PI/

146 The study provides compelling rationale for testing combinations of high-dose AA and a

147 Overall, the data provide a strong rationale for the advanced evaluation of HSD17B12 inhibi

148 These findings provide rationale for the assessment of KEs as a treatment for p

149 sults provide a structural and computational rationale for the catalytic versatility of NzeB, as well

150 C-I molecules for degradation, and provide a rationale for the combination of autophagy inhibition an

151 phasized in the context of the framework and rationale for the development and testing of therapeutic

152 es of mouse and bacterial TSPO and propose a rationale for the development of new ligands for the pro

153 leukemia (AML) with mutated NPM1 provides a rationale for the evaluation of gemtuzumab ozogamicin (G

154 Along with providing the scientific rationale for the evaluation of TGFbeta and PD1 co-block

155 We discuss the rationale for the guidelines and their general content,

156 Our data provide preclinical rationale for the implementation of these lncRNAs and WD

157 We outline a rationale for the inclusion of children in COVID-19 ther

158 s at Dscam2 mutant active zones, providing a rationale for the increase in synaptic strength.

159 Furthermore, we provide a structural rationale for the inhibitory mechanism of ligelizumab.

160 In addition, we provide a molecular rationale for the interaction of the different photoisom

161 tion in multiple hosts provides a compelling rationale for the maintenance of the microbiome homeosta

162 erritin solubility and function, providing a rationale for the presence of ferritin aggregates in cel

163 These findings also provide a rationale for the previously described "olfactory lens,"

164 thesis of the paraherquamides and provided a rationale for the selective spirocyclization of these po

165 counts attributable to introns, provide the rationale for the simultaneous consideration of both exo

166 17q23-amplified breast cancer and provide a rationale for the use of centrosome-targeting therapeuti

167 rived measurements, and provide a compelling rationale for the use of PAC monitoring in patients with

168 al for GvHD diagnosis, and there is a strong rationale for the use of PET tracers that can monitor T-

169 Our findings provide a rationale for the use of selumetinib and AZD8186 in pati

170 m the American Heart Association, we provide rationale for the widespread adoption of rapid diet scre

171 ns, and provided a component in the original rationale for their use in patients with COVID-19, may,

172 derlies T cell leukemogenesis, and provide a rationale for therapeutic targeting of oncogenic MYC via

173 The rationale for these cell therapy trials is derived from

174 A mechanistic rationale for these observations is provided.

175 in the range 122 <= lambda <=155 nm offer a rationale for this apparent depletion; the quantum yield

176 Here we provide the scientific rationale for this approach in the hope that researchers

177 The main rationale for this database is to be able to derive mech

178 The rationale for this decision was the lack of specific pat

179 The biological rationale for this phenomenon is to promote physiologica

180 suffers from diminishing returns, providing rationale for time-limited trials of critical care and s

181 The rationale for tocilizumab treatment is supported by dete

182 These data provide a rationale for treatments effective in depression and sch

183 pression studies do not yet provide a strong rationale for trials of checkpoint inhibitor therapy for

184 y the HLA polymorphic framework, providing a rationale for understanding differences in clinical asso

185 This model, therefore, provides a compelling rationale for understanding how different mutations coop

186 upon ligand binding illuminate a mechanistic rationale for understanding TRPC6 modulation.

187 Collectively, our results provide a rationale for using 8a as a tool compound for functional

188 Only 45 SMTs (37.8%) provided the rationale for using a split-mouth design.

189 ate and adaptive immune cells, and provide a rationale for using CD40L-overexpressing CAR T cells to

190 rts viperin; they also provide a biochemical rationale for viperin's recently discovered role in regu

191 leading an AS program (ASP), we describe the rationale for, and the output and shortcomings of, a ded

192 Results from, timeline and rationale for, cohorts A, B, and C are presented in deta

193 ptive anti-tumor immunity and provide strong rationales for combining telomere-targeting therapy with

194 To illuminate the rationales for sharing data, the technical challenges an

195 lationship of smNBEs in these reactions, and rationales for using smNBEs in many cases have also been

196 Rationale: Gender gaps exist in academic leadership posi

197 Rationale: Genetic association studies have identified r

198 Rationale: Genome-wide association studies have identifi

199 Rationale: Growth and development during adolescence may

200 Rationale: Guidelines for vasopressor titration suggest

201 Rationale: GWAS (Genome-Wide Association Studies) have i

202 Background and Rationale: ICU clinicians regularly care for patients wh

203 Rationale: ICU discharge delay occurs when a patient is

204 Rationale: Identification of younger adults at high risk

205 Rationale: Idiopathic pulmonary fibrosis (IPF) is a comp

206 Rationale: IL-18 is a member of the IL-1 cytokine family

207 Rationale: In December 2016, a single-center study descr

208 Rationale: In patients with chronic obstructive pulmonar

209 Rationale: In the IMPACT (Informing the Pathway of Chron

210 Rationale: Individuals with asthma have heightened antib

211 Rationale: Infection with the severe acute respiratory s

212 Rationale: Inhaled corticosteroids (ICS) are key treatme

213 Rationale: Intraerythrocytic polymerization of Hb S prom

214 Rationale: Invasive tracheobronchial aspergillosis (ITBA

215 t recent instances of electrode choice where rationale is offered, which should aid future reaction d

216 This mechanistic rationale is supported by detailed computational density

217 Rationale: Large decreases in Pa(CO(2)) that occur when

218 Rationale: Limited information is available on racial/et

219 Rationale: Long-term antibiotic use for managing chronic

220 Rationale: Mathematical modeling is used to understand d

221 Rationale: Mechanical forces are transduced to nuclear r

222 Rationale: MicroRNAs are potent regulators of biologic s

223 This study provides the rationale, molecular mechanism, and validation of a clin

224 Rationale: Monitoring and controlling respiratory drive

225 Rationale: Most U.S. residents who develop tuberculosis

226 linical success, the scientific and clinical rationale must be critically evaluated when applying nan

227 Despite their theoretical rationale, nicotinic alpha-7 acetylcholine (nalpha(7)) r

228 e been developed as independent guide design rationales, no library has yet combined these into a sin

229 Rationale: Non-cystic fibrosis bronchiectasis is charact

230 Rationale: Noninvasive ventilation decreases the need fo

231 Rationale: Obesity has been implicated as a pathogenic f

232 Rationale: Obesity hypoventilation syndrome (OHS) has be

233 Rationale: Obesity is the primary risk factor for obstru

234 Rationale: Obesity-related asthma disproportionately aff

235 laboration document describes the intent and rationale of each recommendation and discusses related a

236 alysis of selected Flo11A domains, provide a rationale of how cell surface receptors have evolved in

237 it is important to understand the scientific rationale of pandemic-mitigation strategies such as wear

238 native delivery technique developed with the rationale of providing higher drug concentrations to pos

239 is to clarify both points and explicate the rationale of rationalization.

240 The rationale of this study was to investigate the performan

241 Rationale: Parapneumonic effusions have a wide clinical

242 Rationale: Patients who receive invasive mechanical vent

243 Rationale: Phthalates are a group of chemicals used in c

244 Rationale: Pneumococcal pneumonia remains a global healt

245 Rationale: Primary graft dysfunction (PGD) is the leadin

246 In this Perspective, we describe the rationale, promise and challenges associated with ctDNA-

247 Rationale: Puerto Ricans have the highest childhood asth

248 Rationale: Pulmonary arterial hypertension (PAH) is a li

249 Rationale: Pulmonary hypertension (PH) associated with n

250 Rationale: Pulmonary hypertension (PH) is a life-threate

251 Rationale: Pulmonary rehabilitation (PR) after hospitali

252 Rationale: Recent data show that Aspergillus species are

253 Rationale: Recent studies have revealed that, in critica

254 Rationale: Recently, rare heterozygous mutations in GDF2

255 Rationale: Respiratory syncytial virus (RSV) bronchiolit

256 Rationale: Response to positive end-expiratory pressure

257 Rationale: Rifapentine has been investigated at various

258 Rationale: Several new drugs for idiopathic pulmonary fi

259 Rationale: Sleep deprivation can alter endurance of skel

260 Rationale: Smoking results in at least a decade lower li

261 Rationale: Socioeconomic factors are associated with wor

262 Rationale: Subclinical acute kidney injury (sub-AKI) ref

263 Conversely, theoretical rationales suggest that these agents may benefit patient

264 Our findings provide rationale supporting the clinical development of FAK inh

265 This review discusses the rationale, supporting evidence, opportunities, and chall

266 Rationale: Systemic inflammation compromises the reparat

267 and classification of UTIs, with the common rationale that cUTIs have a higher risk of recurrence or

268 Rationale: The decades-long progression of chronic obstr

269 Rationale: The IMPACT (Informing the Pathway of Chronic

270 Rationale: The impact of coronavirus disease (COVID-19)

271 Rationale: The management of indeterminate pulmonary nod

272 Rationale: The overuse of antibiotics has been an import

273 Rationale: The respiratory tract constitutes an elaborat

274 Rationale: The role of FSTL-1 (follistatin-like 1) in lu

275 Rationale: The role of inspiratory effort still has to b

276 Rationale: The role of PI (protease inhibitor) type Z he

277 Rationale: The World Health Organization recommends the

278 Rationale: The ZZ genotype of alpha-1 antitrypsin defici

279 Rationale: There are no prospective observational studie

280 Rationale: Tidal expiratory flow limitation (tidal-EFL)

281 Rationale: Tissue Doppler imaging (TDI) is an echocardio

282 tamin B-12 or folate biomarkers, there is no rationale to adjust for inflammation when estimating pop

283 y isolated CD8(+) T cells and strengthen the rationale to choose CD2 and AMPK as therapeutic targets

284 Our study provides a strong rationale to evaluate AR as a potential therapeutic targ

285 ncer therapeutics, yet a precise mechanistic rationale to guide clinicians on which to choose for a p

286 ed progression of HIV-1 infection provides a rationale to leverage ADCC-mediating antibodies for trea

287 .5-fold increased risk of MI, supporting the rationale to target IL-1 activation to reduce cardiovasc

288 TNFR1, and mitochondrial ROS, supporting the rationale to target these pathways to mitigate tissue da

289 r division in polyploid cells and provides a rationale to understand chromosome instability typical o

290 Rationale: Treatment of chronic obstructive pulmonary di

291 Rationale: Two distinct phenotypes of acute respiratory

292 Rationale: Uncontrolled inflammatory innate response and

293 The rationale was brought up by the observation of the rever

294 The rationale was to assess whether there are differences in

295 Our rationale was to conduct a retrospective study comparing

296 With this rationale, we established a validated ultra-high-perform

297 Rationale: We have a limited understanding of the molecu

298 stance to heat-related illness amongst their rationales when advising owners on breed selection.

299 Rationale: When stereotactic ablative radiotherapy is an

300 Rationale: Whether critical care improvements over the l